1. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography 
Chelsea C. Pinnix, MD, PhD, Bouthaina Dabaja, MD, Mohamed Amin Ahmed, MD, Hubert H. Chuang, MD, PhD, Colleen Costelloe, MD, Christine F. Wogan, MS, Valerie Reed, MD, Jorge E. Romaguera, MD, Sattva Neelapu, MD, Yasuhiro Oki, MD, M. Alma Rodriguez, MD, Luis Fayad, MD, Frederick B. Hagemeister, MD, Loretta Nastoupil, MD, Francesco Turturro, MD, Nathan Fowler, MD, Michelle A. Fanale, MD, Yago Nieto, MD, PhD, Issa F. Khouri, MD, Sairah Ahmed, MD, L. Jeffrey Medeiros, MD, Richard Eric Davis, MD, Jason Westin, MD 
International Journal of Radiation Oncology • Biology • Physics 
Volume 92, Issue 1, Pages (May 2015)
DOI: /j.ijrobp
Copyright © 2015 The Authors Terms and Conditions

2. Fig. 1
Overall survival (OS) (a) and progression-free survival (PFS) (b) among 97 patients treated for stage I/II primary mediastinal B cell lymphoma.
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © 2015 The Authors Terms and Conditions

3. Fig. 2
Progression-free survival according to type of immunochemotherapy for 97 patients with limited-stage primary mediastinal B-cell lymphoma. R-CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-EPOCH = rituximab plus dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone; R-HCVAD = rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone.
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © 2015 The Authors Terms and Conditions

4. Fig. 3
Median standardized uptake values (SUVs) on positron emission tomography–computed tomography among patients with end-of-immunochemotherapy Deauville 5-point scale of 4-5 with or without relapse.
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © 2015 The Authors Terms and Conditions

5. Fig. 4
Treatment and outcome based on type of chemoimmunotherapy and end-of-treatment PET-CT. (a) R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-EPOCH, rituximab plus dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone. (b) R-HCVAD, R-HCVAD, rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone. (c) R-EPOCH, rituximab plus dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone. ASCT = allogeneic/autologous stem cell transplantation; CCR = continued complete response; chemo = chemotherapy; CR = complete response; PD = progressive disease; PET-CT = positron emission tomography–computed tomography; RT = radiation therapy; sChemo = salvage chemotherapy.
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © 2015 The Authors Terms and Conditions

6. Fig. 5
Progression-free survival (PFS) according to Deauville 5-point scale (5Ps) at the end of initial chemotherapy. (a) 5PS 1-2 versus 5PS 3-5; (b) 5PS 1-3 versus 5PS 4-5. Cum = cumulative.
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © 2015 The Authors Terms and Conditions